Effects of raloxifene administration on serum levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein 3 levels: A systematic review and meta-analysis of randomized controlled trials

IF 1.6 4区 医学 Q4 CELL BIOLOGY Growth Hormone & Igf Research Pub Date : 2021-10-01 DOI:10.1016/j.ghir.2021.101421
Yan Sun , Ying Xiong , Yong Liang Meng , Heitor O. Santos , Felipe L. Athayde , Ivan G.O. de Souza , Ling Yang
{"title":"Effects of raloxifene administration on serum levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein 3 levels: A systematic review and meta-analysis of randomized controlled trials","authors":"Yan Sun ,&nbsp;Ying Xiong ,&nbsp;Yong Liang Meng ,&nbsp;Heitor O. Santos ,&nbsp;Felipe L. Athayde ,&nbsp;Ivan G.O. de Souza ,&nbsp;Ling Yang","doi":"10.1016/j.ghir.2021.101421","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To ascertain the clinical magnitude of raloxifene administration on insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein 3 (IGFBP-3) levels.</p></div><div><h3>Methods</h3><p>A systematic comprehensive search was performed without language limitation up to 14 December 2020. We included only trials that assessed the effect of raloxifene on IGF-1 and IGFBP-3 in adults. Meta-analysis was performed using the Stata software (Stata Corp. College Station, Texas, USA).</p></div><div><h3>Results</h3><p><span>Seven arms were included, encompassing postmenopausal women with type 2 diabetes mellitus, postmenopausal women with breast cancer, healthy postmenopausal women, and healthy elderly men. Raloxifene therapy significantly reduced IGF-1 levels (WMD: −2.92 nmol/L, 95% CI: −3.49, −2.35, </span><em>p</em> &lt; 0.001) compared to placebo. Raloxifene dosage ˃60 mg/day (WMD: −3.29 ng/mL, 95% CI: −3.50 to −3.08, I<sup>2</sup> = 0.0%) decreased IGF-1 levels more than 60 mg/day (WMD: −2.29 ng/mL, 95% CI: −2.90 to −1.69, I<sup>2</sup> = 16%). Moreover, intervention duration ˃26 weeks (WMD: −3.48 ng/mL, 95% CI: −5.26 to −1.69, I<sup>2</sup> = 0.0%) reduced IGF-1 levels more than ˂26 weeks (WMD: −2.55 ng/mL, 95% CI: −3.31 to −1.79, I<sup>2</sup> = 92%). In contrast, overall results from the random-effects model did not suggest a significant change in IGFBP-3 levels upon raloxifene therapy.</p></div><div><h3>Conclusion</h3><p>Raloxifene therapy significantly reduced serum levels of IGF-1 levels but without changes in IGFPB-3 levels.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101421","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Growth Hormone & Igf Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1096637421000447","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Objective

To ascertain the clinical magnitude of raloxifene administration on insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein 3 (IGFBP-3) levels.

Methods

A systematic comprehensive search was performed without language limitation up to 14 December 2020. We included only trials that assessed the effect of raloxifene on IGF-1 and IGFBP-3 in adults. Meta-analysis was performed using the Stata software (Stata Corp. College Station, Texas, USA).

Results

Seven arms were included, encompassing postmenopausal women with type 2 diabetes mellitus, postmenopausal women with breast cancer, healthy postmenopausal women, and healthy elderly men. Raloxifene therapy significantly reduced IGF-1 levels (WMD: −2.92 nmol/L, 95% CI: −3.49, −2.35, p < 0.001) compared to placebo. Raloxifene dosage ˃60 mg/day (WMD: −3.29 ng/mL, 95% CI: −3.50 to −3.08, I2 = 0.0%) decreased IGF-1 levels more than 60 mg/day (WMD: −2.29 ng/mL, 95% CI: −2.90 to −1.69, I2 = 16%). Moreover, intervention duration ˃26 weeks (WMD: −3.48 ng/mL, 95% CI: −5.26 to −1.69, I2 = 0.0%) reduced IGF-1 levels more than ˂26 weeks (WMD: −2.55 ng/mL, 95% CI: −3.31 to −1.79, I2 = 92%). In contrast, overall results from the random-effects model did not suggest a significant change in IGFBP-3 levels upon raloxifene therapy.

Conclusion

Raloxifene therapy significantly reduced serum levels of IGF-1 levels but without changes in IGFPB-3 levels.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
雷洛昔芬对血清胰岛素样生长因子-1和胰岛素样生长因子结合蛋白3水平的影响:随机对照试验的系统回顾和荟萃分析
目的探讨雷洛昔芬对胰岛素样生长因子-1 (IGF-1)和胰岛素样生长因子结合蛋白3 (IGFBP-3)水平的影响。方法截至2020年12月14日,进行无语言限制的系统综合检索。我们只纳入了评估雷洛昔芬对成人IGF-1和IGFBP-3影响的试验。meta分析采用Stata软件(Stata Corp. College Station, Texas, USA)。结果纳入7组,包括绝经后2型糖尿病妇女、绝经后乳腺癌妇女、健康绝经后妇女和健康老年男性。雷洛昔芬治疗显著降低IGF-1水平(WMD:−2.92 nmol/L, 95% CI:−3.49,−2.35,p <0.001)。雷洛昔芬剂量≤60 mg/天(WMD:−3.29 ng/mL, 95% CI:−3.50 ~−3.08,I2 = 0.0%)可降低IGF-1水平(WMD:−2.29 ng/mL, 95% CI:−2.90 ~−1.69,I2 = 16%)。此外,干预时间≤26周(WMD:−3.48 ng/mL, 95% CI:−5.26 ~−1.69,I2 = 0.0%)比≤26周(WMD:−2.55 ng/mL, 95% CI:−3.31 ~−1.79,I2 = 92%)降低了IGF-1水平。相比之下,随机效应模型的总体结果并未显示雷洛昔芬治疗后IGFBP-3水平有显著变化。结论雷洛昔芬治疗可显著降低血清IGF-1水平,但对IGFPB-3水平无明显影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Growth Hormone & Igf Research
Growth Hormone & Igf Research 医学-内分泌学与代谢
CiteScore
3.30
自引率
0.00%
发文量
38
审稿时长
57 days
期刊介绍: Growth Hormone & IGF Research is a forum for research on the regulation of growth and metabolism in humans, animals, tissues and cells. It publishes articles on all aspects of growth-promoting and growth-inhibiting hormones and factors, with particular emphasis on insulin-like growth factors (IGFs) and growth hormone. This reflects the increasing importance of growth hormone and IGFs in clinical medicine and in the treatment of diseases.
期刊最新文献
The association between change in temporal muscle mass and treatment of acromegaly Editorial Board Medical treatment of acromegaly – When the tumor size matters: A narrative review Editorial Board Adult patients with Laron syndrome tend to develop the metabolic syndrome
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1